Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients

AstraZeneca

Status: Completed

Conditions: Primary Hypertension

Treatments: Drug: Candesartan Cilexeotil 16mg

Study type: Observational

Funder types: Industry

Identifiers

NCT00573742

NIS-CRO-ATA-2007/1

Details and patient eligibility

About

The purpose of this study is to observe treatment with candesartan cilexetil 16mg for 8 weeks, in uncontrolled hypertensive patients, in improvement of achieving of treatment goals and impact on blood pressure level in patients with uncontrolled hypertension treated with candesartan cilexetil.

Enrollment: 1,940 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of essential hypertension (mild or moderate as defined in European Guidelines of Hypertension, 2003), that are treated already with candesartan cilexetil 16mg o.d. within last 2 weeks or more, according to Romanian approved Atacand SPC. Written informed consent to allow access and use(analysis) of data collected

Exclusion criteria

• Patients not to be included in the programme: patients who have any contraindication to the product as detailed in Romanian approved Atacand SPC. Use of specific concomitant medication known to present a potential safety concern according to Romanian approved SPC